Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX
Quoin Pharmaceuticals — Cellect Biotechnology — Investor Presentation (April 2019)
21 slides from Quoin Pharmaceuticals's investor presentation, Apr 30, 2019
Slide 1: Enabling regenerative medicine May 2019
Enabling regenerative medicine May 2019
Slide 2: Forward-looking statements
This presentation includes statements that are, or may be deemed, ‘‘forward - looking statements . ” In some cases, these forward - looking statements can be identified by the use of forward - looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “inten
Slide 3: Table of Content
TABLE OF CONTENT Our core story Next NEXT IN MEDICINE THE WAY THE NEED THE CHALLENGE THE SOLUTION - CELLECT THE TECHNOLOGY THE DIFFERENTIATION IMMEDIATE MARKET BUSINESS MODEL STRONG IP PORTFOLIO TIMELINE TEAM BOARD & ADVISORY BOARD 3 COMMERCILAIZATION
Slide 4: Next in Medicine
NEXT IN MEDICINE Replacing tissues and organs instead of fixing them REGENRATIVE MEDICINE CAN REVOLUTIONIZE TREATMENTS OF DIABETES ORTHOPEDIC TISSUE REPAIR SPINAL CORD DAMAGE HEART DISEASE LIVER DISEASE CANCER AND MANY MORE
Slide 5: Immediate Market
IMMEDIATE MARKET Hundreds of regenerative medicine products under FDA approval route PHARMA COMPANIES - NOVARTIS, GILEAD RESEARCH CENTERS - HARVARD CLINICAL TRIALS - WASHINGTON UNIVERSITY
Slide 6: FDA 2019
FDA 2019 • “ … The FDA plans to hire at least 50 new clinical reviewers tasked with assessing cell and gene therapies to prepare for what the agency describes as a surge of cutting - edge products … • … the agency expects to receive at least 200 new drug (IND) applications annually … The FDA predict
Slide 7: The Way
THE WAY Use stem cells as raw material for ‘replacement parts’
Slide 8: The Need
THE NEED $15.63 B stem cells market by 2025 * supporting global regenerative medicine development Hundreds of treatments under FDA route requiring substantial funds for safe, enriched and high - quality stem cells * GRANDVIEW RESEARCH 2019
Slide 9: The Challenge
THE CHALLENGE Current methods of stem cells production do not deliver 2025 DEMAND POTENTIAL SUPPLY THE GAP NON - STANDARD TIME CONSUMING EXTREMELY EXPENSIVE TOXIC $15.63 B
Slide 10: The Solution - Cellect
THE SOLUTION - CELLECT The only current solution for safe, mass production and supply of enriched, high - quality stem cells 2025 DEMAND POTENTIAL SUPPLY CELLECT $15.63 B
Slide 11: First Product – Apotainer
FIRST PRODUCT – APOTAINER™ Para - magnetic micro - beads - based system coated with human protein that specifically eliminates the harming cells out of a cells mass Value proposition SAFE FAST AFFORDABLE
Slide 12: Second Product – Fat Stem Cells
SECOND PRODUCT – FAT STEM CELLS Proprietary matrix - coated with human protein that naturally enhances the stem cells expansion in quality and quantity Value proposition SAFE FAST AFFORDABLE
Slide 13: The Differentiation
THE DIFFERENTIATION CURRENT SOLUTIONS CELLECT’S VALUE PROPOSITION COST - EFFECTIVE FAST SAFE SCALABLE EXPENSIVE TAKES WEEKS TOXIC NOT SCALABLE
Slide 14: Why Now
WHY NOW Convergence point 2019 2025 MARKET CELLECT POC BUSINESS DEVELOPMENT R&D R&D BLOOD & FAT DERIVED STEM CELLS CANCER, DIABETES, TRANSPLANTS AND POSITIVE CLINICAL RESULTS APOGRAFT APOTAINER OUTLICENSING PHARMA COMPANIES MEDICAL & RESEARCH CENTERS FDA BUSINESS DEMAND CELL THERAPY MORE THAN 800 AC
Slide 15: Business Model
BUSINESS MODEL Out licensing with upfront fees + royalties 879 LICENSING DEALS IN LIFE SCIENCES SECTOR, Q1/2018; DISCLOSED VALUE OF ~$35.2B ENTEROME, GLOBAL LISENCING AND CO - DEVELOPMENT WITH TAKEDA; $50M UPFRONT + $640M IN MILESTONES
Slide 16: Strong IP Portfolio
STRONG IP PORTFOLIO 65 patents owned by the Company with 32 already approved USING APOPTOSIS - INDUCING AGENTS FOR STEM CELLS SELECTION - GRANTED COMPOSITION OF MATTER OF APOTAINERS™ - GRANTED METHODS OF USE - GRANTED METHOD OF MANUFACTURING APOTAINERS™ - GRANTED MESENCHYMAL STEM CELLS SELECTION EXP
Slide 17: Timeline
TIMELINE Business development in process with expected first licensing & royalties deals within 18 months SALES TO PHARMA COMPANIES ARE EXPECTED TO NOT REQUIRE FDA APPROVAL BEYOND SAFETY
Slide 18: Team
TEAM JONATHAN BURGIN A NASDAQ Company CFO ADVISORY BOARD BOARD MANAGEMENT
Slide 19: Commercialization Next
COMMERCILAIZATION NEXT 19
Slide 20: Thank you
Thank you
Slide 21: Results
RESULTS • Strong Pre - Clinical Data • Multiple animal models (i . e . cancer, Diabetes (T 1 ), orthopedics and transplantation) • > 200 human bone marrow donor samples tested • Human clinical trial – half study population recruited – mid study results published 0 20 40 60 80 100 0 2 4 6 8 Time (day
Cellect Biotechnology — Investor Presentation (April 2019) on 6ix